《肾移植受者直接抗病毒疗法根除丙型肝炎病毒感染》勘误
Erratum to "Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients".
作者信息
Calogero Armando, Sagnelli Evangelista, Creta Massimiliano, Angeletti Silvia, Peluso Gaia, Incollingo Paola, Candida Maria, Minieri Gianluca, Carlomagno Nicola, Dodaro Concetta Anna, Ciccozzi Massimo, Sagnelli Caterina
机构信息
Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
Department of Mental Health and Public Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
出版信息
Biomed Res Int. 2019 Jul 15;2019:8797329. doi: 10.1155/2019/8797329. eCollection 2019.
Abstract
[This corrects the article DOI: 10.1155/2019/4674560.].
摘要
[本文更正文章DOI：10.1155/2019/4674560。]
相似文献
1
Erratum to "Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients".《肾移植受者直接抗病毒疗法根除丙型肝炎病毒感染》勘误
Biomed Res Int. 2019 Jul 15;2019:8797329. doi: 10.1155/2019/8797329. eCollection 2019.
2
Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient.直接作用抗病毒疗法治疗肾移植受者丙型肝炎病毒感染。
Kidney Int. 2018 Mar;93(3):560-567. doi: 10.1016/j.kint.2017.10.024. Epub 2018 Jan 9.
3
Use of HCV+ Donors Does Not Affect HCV Clearance With Directly Acting Antiviral Therapy But Shortens the Wait Time to Kidney Transplantation.使用 HCV+ 供者不会影响直接作用抗病毒治疗清除 HCV，但会缩短等待肾移植的时间。
Transplantation. 2017 May;101(5):968-973. doi: 10.1097/TP.0000000000001410.
4
Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients.新型无干扰素治疗根除丙型肝炎病毒可改善丙型肝炎病毒相关肝移植受者的代谢特征。
Liver Transpl. 2018 Aug;24(8):1031-1039. doi: 10.1002/lt.25060.
5
Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis.直接抗病毒药物（达拉他韦和阿舒瑞韦）联合治疗方案治疗慢性丙型肝炎病毒 1 型感染合并血液透析患者的安全性和疗效。
J Gastroenterol. 2016 Jul;51(7):741-7. doi: 10.1007/s00535-016-1174-4. Epub 2016 Feb 12.
6
[Novel antiviral agents for the treatment of HCV among renal transplant recipients].[用于治疗肾移植受者丙型肝炎病毒感染的新型抗病毒药物]
G Ital Nefrol. 2017 Aug 1;34(4):35-50.
7
Amino acid substitutions in the hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by all-oral direct-acting antiviral regimens.丙型肝炎病毒核心区的氨基酸替换可预测在全口服直接作用抗病毒治疗方案消除 HCV RNA 后发生肝癌。
J Med Virol. 2018 Jun;90(6):1087-1093. doi: 10.1002/jmv.25047. Epub 2018 Feb 26.
8
Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection.基于索磷布韦的疗法成功治疗合并感染人类免疫缺陷病毒/丙型肝炎病毒的肝移植受者复发性丙型肝炎病毒感染
AIDS. 2016 Jan 2;30(1):93-8. doi: 10.1097/QAD.0000000000000887.
9
Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C.无干扰素抗病毒治疗在慢性丙型肝炎肾移植受者中的疗效和耐受性。
J Hepatol. 2017 Apr;66(4):718-723. doi: 10.1016/j.jhep.2016.12.020. Epub 2016 Dec 28.
10
Corrigendum: Direct-acting antiviral agents in Hepatitis C Virus infected renal allograft recipients: Treatment and outcome experience from single center.勘误：丙型肝炎病毒感染的肾移植受者中的直接抗病毒药物：单中心的治疗及结果经验
Indian J Nephrol. 2018 Jul-Aug;28(4):333. doi: 10.4103/0971-4065.238576.
引用本文的文献
1
Gastroenterological complications in kidney transplant patients.肾移植患者的胃肠并发症
Open Med (Wars). 2020 Jul 11;15(1):623-634. doi: 10.1515/med-2020-0130. eCollection 2020.
2
Cancer- and Non-cancer Related Chronic Pain: From the Physiopathological Basics to Management.癌症及非癌症相关慢性疼痛：从生理病理基础到管理
Open Med (Wars). 2019 Oct 17;14:761-766. doi: 10.1515/med-2019-0088. eCollection 2019.
本文引用的文献
1
Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients.肾移植受者应用直接作用抗病毒药物清除 HCV 感染。
Biomed Res Int. 2019 Apr 7;2019:4674560. doi: 10.1155/2019/4674560. eCollection 2019.
Zotero 插件